bristol-myers squibb stock news - Search News

Bristol Myers Squibb Stock Rises

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.

Why Did Bristol-Myers Squibb Co (BMY) Stock See 34.20% Surge in the Last 90 Days?

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at $52.

MarketWatch on MSN · 6d

Bristol-Myers Squibb stock jumps on schizophrenia drug approval

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.

2d

Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

17h

2 Passive-Income Stocks to Load Up On in October

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

2d

Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

3d

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

1h

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results